Breaking News, Promotions & Moves

Neurizon Adds Strategic Regulatory and Scientific Leadership

New appointments will provide the company with broader expertise in regulatory affairs, clinical development and commercialization.

Author Image

By: Charlie Sternberg

Associate Editor

Neurizon Therapeutics Limited, a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has strengthened its executive management team with three key appointments: Ms. Kathryn Williams as Chief Regulatory Officer (CRO) Dr. Jeffrey M. Brown as Chief Scientific Advisor (CSA) Dr. Chris Freitag as Chief Medical Advisor (CMA) These appointments provide the Company with broader expertise in regulatory affairs, clinical development and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters